- Jean-Pierre Garnier said it had been a "difficult year"
- The company had absorbed over Â£1.5bn of lost sales to generics but was still managing to grow the business
- "2005 will also be an important year in terms of research and development pipeline progress."
- The firm discontinued development of an experimental treatment for obesity, known as '771, after disappointing clinical trial results
